Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling
has been revised, including updated immunostaining images and corresponding data for Ki67-and CD31-positive cells in both the control and raloxifene-treated groups.Following Editor approval, Figure 4, as well as sections 2.8 and 3.8 of the article, have been updated accordingly.
Authors
- Ioannis Pozios (ORCID: https://orcid.org/0000-0002-3462-9822)
- Nina N. Seel
- Martin E. Kreis (ORCID: https://orcid.org/0000-0002-9312-4840)
- Christiane J. Bruns (ORCID: https://orcid.org/0000-0001-6590-8181)
- Lucas D. Lee (ORCID: https://orcid.org/0000-0001-5729-0537)
- Verena Liu
- Nina A. Hering (ORCID: https://orcid.org/0000-0001-9751-6967)
- Hendrik Seeliger (ORCID: https://orcid.org/0000-0002-5937-052X)
- Peter Čamaj
- Lisa Hartmann (ORCID: https://orcid.org/0000-0003-3494-2269)
- Mario H. Müller
Institutions
- LMU Klinikum (DE)
- Vivantes Klinikum (DE)
- München Klinik (DE)
- University Hospital Cologne (DE)
- Franklin University (US)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1007/s13402-025-01128-8
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00